Amyloidosis is a group of diseases in which abnormal proteins, known as amyloid fibrils, build up in tissue. There are several non-specific and vague signs and symptoms associated with amyloidosis. These include: fatigue, peripheral edema, weight loss, shortness of breath, palpitations, and feeling faint with standing. In AL amyloidosis, specific indicators can include enlargement of the tongue and periorbital purpura. In wild-type ATTR amyloidosis, non-cardiac symptoms include: bilateral carpal tunnel syndrome, lumbar spinal stenosis, bicep tendon rupture, small fiber neuropathy, and autonomic dysfunction.
|Classic facial features of AL amyloidosis with bleeding under the skin (bruising) around the eyes|
|Specialty||Hematology, Endocrinology, rheumatology, cardiology|
|Symptoms||Feeling tired, weight loss, swelling of the legs, shortness of breath, bleeding, feeling light headed with standing|
|Usual onset||55–65 years old|
|Causes||Genetic or acquired|
|Diagnostic method||Tissue biopsy|
|Treatment||Supportive care, directed at the underlying cause, dialysis, organ transplantation|
|Prognosis||Improved with treatment|
|Frequency||3–13 per million per year (AL amyloidosis)|
|Deaths||1 per 1,000 people (developed world)|
There are about 36 different types of amyloidosis, each due to a specific protein misfolding. Within these 36 proteins, 19 are grouped into localized forms, 14 are grouped as systemic forms, and 3 proteins can identify as either. These proteins can become irregular due to genetic effects, as well as through acquired environmental factors. The four most common types of systemic amyloidosis are light chain (AL), inflammation (AA), dialysis-related (Aβ2M), and hereditary and old age (ATTR and familial amyloid polyneuropathy).
Diagnosis may be suspected when protein is found in the urine, organ enlargement is present, or problems are found with multiple peripheral nerves and it is unclear why. Diagnosis is confirmed by tissue biopsy. Due to the variable presentation, a diagnosis can often take some time to reach.
Treatment is geared towards decreasing the amount of the involved protein. This may sometimes be achieved by determining and treating the underlying cause. AL amyloidosis occurs in about 3–13 per million people per year and AA amyloidosis in about 2 per million people per year. The usual age of onset of these two types is 55 to 60 years old. Without treatment, life expectancy is between six months and four years. In the developed world about 1 per 1,000 people die annually from amyloidosis. Amyloidosis has been described since at least 1639.
Signs and symptomsEdit
The presentation of amyloidosis is broad and depends on the site of amyloid accumulation. The kidney and heart are the most common organs involved.
Amyloid deposition in the kidney often involve the glomerular capillaries and mesangial regions, affecting the organ’s ability to filter and excrete waste and retain plasma protein. This can lead to high levels of protein in the urine (proteinuria) and nephrotic syndrome. Several types of amyloidosis, including the AL and AA types, are associated with nephrotic syndrome. Approximately 20% and 40-60% of people with AL and AA amyloidosis respectively progress to end-stage kidney disease requiring dialysis.
Amyloid deposition in the heart can cause both diastolic and systolic heart failure. EKG changes may be present, showing low voltage and conduction abnormalities like atrioventricular block or sinus node dysfunction.[medical citation needed] On echocardiography, the heart shows a restrictive filling pattern, with normal to mildly reduced systolic function. AA amyloidosis usually spares the heart. Cardiac amyloidosis can present with symptoms of heart failure including shortness of breath, fatigue, and edema. As cardiac amyloidosis progresses, the amyloid deposition can affect the heart's ability to pump and fill blood as well as its ability to maintain normal rhythm, which leads to worsening heart function and decline in people's quality of life.
People with amyloidosis do not get central nervous system involvement but can develop sensory and autonomic neuropathies.[medical citation needed] Sensory neuropathy develops in a symmetrical pattern and progresses in a distal to proximal manner. Autonomic neuropathy can present as orthostatic hypotension but may manifest more gradually with nonspecific gastrointestinal symptoms like constipation, nausea, or early satiety.
Neuropathic presentation can depend on the etiology of amyloidosis. People with amyloidosis may experience dysfunction in various organ systems depending on the location and extent of nervous system involvement. For example, peripheral neuropathy can cause erectile dysfunction, incontinence and constipation, pupillary dysfunction, and sensory loss depending on the distribution of amyloidosis along different peripheral nerves. Amyloidosis of the central nervous system can have more severe and systemic presentations that may include life-threatening arrhythmias, cardiac failure, malnutrition, infection, or death.
Gastrointestinal and Accessory OrgansEdit
Accumulation of amyloid proteins in the gastrointestinal system may be caused by a wide range of amyloid disorders and have different presentations depending on the degree of organ involvement. Potential symptoms include weight loss, diarrhea, abdominal pain, heartburn (gastrointestinal reflux), and GI bleeding. Amyloidosis may also affect accessory digestive organs including the liver, and may present with jaundice, fatty stool, anorexia, fluid buildup in the abdomen, and spleen enlargement.
Accumulation of amyloid proteins in the liver can lead to elevations in serum aminotransferases and alkaline phosphatase, two biomarkers of liver injury, which is seen in about one third of people. Liver enlargement is common. In contrast, spleen enlargement is rare, occurring in 5% of people. Splenic dysfunction, leading to the presence of Howell-Jolly bodies on blood smear, occurs in 24% of people with amyloidosis. Malabsorption is seen in 8.5% of AL amyloidosis and 2.4% of AA amyloidosis. One suggested mechanism for the observed malabsorption is that amyloid deposits in the tips of intestinal villi (fingerlike projections that increase the intestinal area available for absorption of food), begin to erode the functionality of the villi, presenting a sprue-like picture.
Both the thyroid and adrenal glands can be infiltrated. It is estimated that 10–20% of people with amyloidosis have hypothyroidism. Adrenal infiltration may be harder to appreciate given that its symptoms of orthostatic hypotension and low blood sodium concentration may be attributed to autonomic neuropathy and heart failure.
"Amyloid deposits occur in the pancreas of people who also have diabetes mellitus, although it is not known if this is functionally important. The major component of pancreatic amyloid is a 37-amino acid residue peptide known as islet amyloid polypeptide or 'amylin.' This is stored with insulin in secretory granules in B cells and is co secreted with insulin." (Rang and Dale's Pharmacology, 2015.)
Amyloid proteins deposit most commonly inside the knee, followed by hands, wrists, elbow, hip, and ankle, causing joint pain. In males with advanced age (>80 years), there is significant risk of wild-type transthyretin amyloid deposition in synovial tissue of knee joint, but predominantly in old age deposition of wild type transthyretin is seen in cardiac ventricles. ATTR deposits have been found in ligamentum flavum of patients that underwent surgery for lumbar spinal stenosis.
In beta 2-microglobulin amyloidosis, males have high risk of getting carpal tunnel syndrome. Aβ2MG amyloidosis (Hemodialysis associated amyloidosis) tends to deposit in synovial tissue, causing chronic inflammation of the synovial tissue in knee, hip, shoulder and interphalangeal joints. Amyloid light chains deposition in shoulder joint causes enlarged shoulders, also known as "shoulder pad sign". Amyloid light chain depositions can also cause bilateral symmetric polyarthritis.
The deposition of amyloid proteins in the bone marrow without causing plasma cell dyscrasias is called amyloidoma. It is commonly found in cervical, lumbar, and sacral vertebrae. Those affected may be presented with bone pain due to bone lysis, lumbar paraparesis, and a variety of neurological symptoms. Vertebral fractures are also common.
A rare development is amyloid purpura, a susceptibility to bleeding with bruising around the eyes, termed "raccoon-eyes". Amyloid purpura is caused by amyloid deposition in the blood vessels and reduced activity of thrombin and factor X, two clotting proteins that lose their function after binding with amyloid.
Amyloid deposits in tissue can cause enlargement of structures. Twenty percent of people with AL amyloidosis have an enlarged tongue, that can lead to obstructive sleep apnea, difficulty swallowing, and altered taste. Tongue enlargement does not occur in ATTR or AA amyloidosis. Deposition of amyloid in the throat can cause hoarseness.
Amyloidoses can be considered protein misfolding diseases. The vast majority of proteins that have been found to form amyloid deposits are secreted proteins, so the misfolding and formation of amyloid occurs outside cells, in the extracellular space. Of the 37 proteins so far identified as being vulnerable to amyloid formation, only four are cytosolic. Most amyloid-forming proteins are relatively small, but otherwise there is currently no evidence of structural or functional similarities among proteins known to form disease-associated amyloids. One third of amyloid disease is hereditary, in which case there is normally an early age of onset. Half of amyloid-related diseases are sporadic and have a late age of onset – in these cases, the protein aggregation may be associated with aging-related decline in protein regulation. Rarely, some medical treatments are associated with amyloid disease.
Amyloid-forming proteins aggregate into distinctive fibrillar forms with a beta-sheet structure. The beta-sheet form of amyloid is proteolysis-resistant, meaning it can not be degraded or broken down. As a result, amyloid deposits into the body’s extracellular space. The process of forming amyloid fibrils is thought to have intermediate oligomeric forms. Both the oligomers and amyloid fibrils can be toxic to cells and can interfere with proper organ function. The relative significance of different aggregation species may depend on the protein involved and the organ system affected.
Diagnosis of amyloidosis generally requires tissue biopsy. The biopsy is assessed for evidence of characteristic amyloid deposits. The tissue is treated with various stains. The most useful stain in the diagnosis of amyloid is Congo red, which, combined with polarized light, makes the amyloid proteins appear apple-green on microscopy. Also, thioflavin T stain may be used. A number of imaging techniques such as a DPD scan or SAP scan are also in use.
A sample of tissue can be biopsied or obtained directly from the affected internal organ, but the first-line site of biopsy is subcutaneous abdominal fat, known as a "fat pad biopsy", due to its ease of acquisition. An abdominal fat biopsy is not completely sensitive and may result in false negatives, which means a negative result does not exclude the diagnosis of amyloidosis. However, direct biopsy of the affected organ may still be unnecessary as other less invasive methods of biopsy can also be used, including rectal mucosa, salivary gland, lip, or bone marrow biopsy which can achieve a diagnosis in up to 85% of people.
In the amyloid deposition of the joints, there will be a decreased signal in both T1 and T2 weighted MRI images. In amyloidoma, there will be low T1 signal with gadolinium injection and low T2 signal.
The type of the amyloid protein can be determined in various ways: the detection of abnormal proteins in the bloodstream (on protein electrophoresis or light chain determination); binding of particular antibodies to the amyloid found in the tissue (immunohistochemistry); or extraction of the protein and identification of its individual amino acids. Immunohistochemistry can identify AA amyloidosis the majority of the time, but can miss many cases of AL amyloidosis. Laser microdissection with mass spectrometry is the most reliable method of identifying the different forms of amyloidosis.
AL was previously considered the most common form of amyloidosis, and a diagnosis often begins with a search for plasma cell dyscrasia, memory B cells producing aberrant immunoglobulins or portions of immunoglobulins. Immunofixation electrophoresis of urine or serum is positive in 90% of people with AL amyloidosis. Immunofixation electrophoresis is more sensitive than regular electrophoresis but may not be available in all centers. Alternatively immunohistochemical staining of a bone marrow biopsy looking for dominant plasma cells can be sought in people with a high clinical suspicion for AL amyloidosis but negative electrophoresis.
ATTR is now considered to be the most common form of amyloidosis, and no longer considered as a rare disease. It may be either age related in wild-type ATTR (ATTRv) or familial transthyretin-associated amyloidosis, is suspected in people with family history of idiopathic neuropathies or heart failure who lack evidence of plasma cell dyscrasias. ATTR can be identified using isoelectric focusing which separates mutated forms of transthyretin. Findings can be corroborated by genetic testing to look for specific known mutations in transthyretin that predispose to amyloidosis.
AA is suspected on clinical grounds in individuals with longstanding infections or inflammatory diseases. AA can be identified by immunohistochemistry staining.
Amyloidosis, dystrophic calcification
Historical classification systems were based on clinical factors. Until the early 1970s, the idea of a single amyloid substance predominated. Various descriptive classification systems were proposed based on the organ distribution of amyloid deposits and clinical findings. Most classification systems included primary (i.e., idiopathic) amyloidosis, in which no associated clinical condition was identified, and secondary amyloidosis (i.e., secondary to chronic inflammatory conditions). Some classification systems included myeloma-associated, familial, and localized amyloidosis.
The modern era of amyloidosis classification began in the late 1960s with the development of methods to make amyloid fibrils soluble. These methods permitted scientists to study the chemical properties of amyloids.[medical citation needed] Descriptive terms such as primary amyloidosis, secondary amyloidosis, and others (e.g., senile amyloidosis), which are not based on cause, provide little useful information and are no longer recommended.
The modern classification of amyloid disease tends to use an abbreviation of the protein that makes the majority of deposits, prefixed with the letter A. For example, amyloidosis caused by transthyretin is termed "ATTR".[medical citation needed] Deposition patterns vary between people but are almost always composed of just one amyloidogenic protein. Deposition can be systemic (affecting many different organ systems) or organ-specific. Many amyloidoses are inherited, due to mutations in the precursor protein.[medical citation needed]
Other forms are due to different diseases causing overabundant or abnormal protein production – such as with overproduction of immunoglobulin light chains (termed AL amyloidosis), or with continuous overproduction of acute phase proteins in chronic inflammation (which can lead to AA amyloidosis).[medical citation needed]
All amyloid fibril proteins start with the letter "A" followed by the protein suffix (and any applicable specification). See below for a list of amyloid fibril proteins which have been found in humans:
|Fibril protein||Precursor protein||Target Organs||Systemic and/or localized||Acquired or hereditary|
|AL||Immunoglobulin light chain||All organs, usually except CNS||S, L||A, H|
|AH||Immunoglobulin heavy chain||All organs except CNS||S, L||A|
|AA||(Apo) serum amyloid A||All organs except CNS||S||A|
|ATTR||Transthyretin, wild type
|Heart mainly in males, lung, ligaments, tenosynovium
PNS, ANS, heart, eye, leptomeninges
|Aβ2M||β2-microglobulin, wild type
|AApoAI||Apolipoprotein A I, variants||Heart, liver, kidney, PNS, testis, larynx (C
terminal variants), skin (C terminal variants)
|AApoAII||Apolipoprotein A II, variants||Kidney||S||H|
|AApoAIV||Apolipoprotein A IV, wild type||Kidney medulla and systemic||S||A|
|AApoCII||Apolipoprotein C II, variants||Kidney||S||H|
|AApoCIII||Apolipoprotein C III, variants||Kidney||S||H|
|AGel||Gelsolin, variants||Kidney, PNS, cornea||S||H|
|ALECT2||Leukocyte chemotactic factor-2||Kidney, primarily||S||A|
|AFib||Fibrinogen a, variants||Kidney, primarily||S||H|
|ACys||Cystatin C, variants||CNS, PNS, skin||S||H|
|Aβ||Aβ protein precursor, wild type
Aβ protein precursor, variant
|APrP||Prion protein, wild type
Prion protein variants
Prion protein variant
|CJD, fatal insomnia
CJD, GSS syndrome, fatal insomnia
|ACal||(Pro)calcitonin||C-cell thyroid tumours
|AIAPP||Islet amyloid polypeptidec||Islets of Langerhans, insulinomas||L||A|
|AANF||Atrial natriuretic factor||Cardiac atria||L||A|
|APro||Prolactin||Pituitary prolactinomas, aging pituitary||L||A|
|AIns||Insulin||Iatrogenic, local injection||L||A|
|ASPCd||Lung surfactant protein||Lung||L||A|
|ACor||Corneodesmosin||Cornified epithelia, hair follicles||L||A|
|AMed||Lactadherin||Senile aortic, media||L||A|
|AOAAP||Odontogenic ameloblast-associated protein||Odontogenic tumours||L||A|
|ASem1||Semenogelin 1||Vesicula seminalis||L||A|
|ACatKe||Cathepsin K||Tumour associated||L||A|
|AEFEMP1e||EGF-containing fibulin-like extracellular
matrix protein 1 (EFEMP1)
|Portal veins, Aging associated||L||A|
An older clinical method of classification refers to amyloidoses as systemic or localised:
- Systemic amyloidoses affect more than one body organ or system. Examples are AL, AA and Aβ2m.
- Localised amyloidoses affect only one body organ or tissue type. Examples are Aβ, IAPP, Atrial natriuretic factor (in isolated atrial amyloidosis), and Calcitonin (in medullary carcinoma of the thyroid)
Another classification is primary or secondary.[medical citation needed]
- Primary amyloidoses arise from a disease with disordered immune cell function, such as multiple myeloma or other immunocyte dyscrasias.
- Secondary (reactive) amyloidoses occur as a complication of some other chronic inflammatory or tissue-destroying disease. Examples are reactive systemic amyloidosis and secondary cutaneous amyloidosis.
Additionally, based on the tissues in which it is deposited, it is divided into mesenchymal (organs derived from mesoderm) or parenchymal (organs derived from ectoderm or endoderm).[medical citation needed]
Treatment depends on the type of amyloidosis that is present. Treatment with high dose melphalan, a chemotherapy agent, followed by stem cell transplantation has shown promise in early studies and is recommended for stage I and II AL amyloidosis. However, only 20–25% of people are eligible for stem cell transplant. Chemotherapy treatment including cyclophosphamide-bortezomib-dexamethasone is currently the recommended treatment option for people with AL Amyloidosis not eligible for transplant.
In AA, symptoms may improve if the underlying condition is treated. In people who have inflammation caused by AA amyloidosis, tumour necrosis factor (TNF)-alpha inhibitors such as infliximab and etanercept are used for an average duration of 20 months. If TNF-alpha inhibitors are not effective, Interleukin-1 inhibitors (e.g. anakinra, canakinumab, rilonacept) and interleukin-6 inhibitors (e.g. tocilizumab) may be considered.
Management of ATTR amyloidosis will depend on its classification as wild type or variant. Both may be treated with tafamidis, a low toxicity oral agent that prevents destabilization of correctly folded protein. Studies showed tafamidis reduced mortality and hospitalization due to heart failure. Previously, for variant ATTR amyloidosis, liver transplant was the only effective treatment. New therapies include diflunisal, inotersen, and patisiran.
Diflunisal binds to misfolded mutant TTR protein to prevent its buildup, like how tafamidis works. Low-certainty evidence indicates that it mitigates worsening of peripheral neuropathy and disability from disease progression.
Inotersen blocks gene expression of both wild-type and mutant TTR, reducing amyloid precursor. Moderate-certainty evidence suggests that it mitigates worsening of peripheral neuropathy. Long-term efficacy and safety of inotersen use in people with mutant TTR-related amyloidosis is still be evaluated in a phase-III clinical trial as of 2021. Both diflunisal and inotersen may also mitigate declines in quality-of-life, though the evidence for this effect is unclear. For people with cardiac ATTR the effect of inotersen use is inconclusive and requires further investigation. In 2018, inotersen was approved by the European Medicines Agency to treat polyneuropathy in adults with hereditary transthyretin amyloidosis. It has since been approved for use in Canada, the European Union and in the USA.
Patisiran functions similarly to inotersen. Moderate-certainty evidence suggests that patisiran mitigates worsening of peripheral neuropathy and disability from disease progression. Additionally, low-certainty evidence suggests that patisiran mitigates decreases in quality-of-life and slightly reduces the rate of adverse events versus placebo. There is no evidence of an effect on mortality rate. A review of early data from use of patisiran in people with variant cardiac ATTR suggests that it may reduce mortality and hospitalization, however this is still being investigated and requires further investigation. In 2018, patisiran was not recommended by NICE in the UK for hereditary transthyretin-related amyloidosis. As of July 2019 further review however is occurring. It was approved for this use in the United States, however.
The roles of inotersen and patisiran in cardiac ATTR amyloidosis are still being investigated.
In 2021, in a clinical trial using the CRISPR gene-editing technique, several participants had an "80% to 96% drop in TTR levels, on par or better than the average of 81%" who were given patisiran.
Prognosis varies with the type of amyloidosis and the affected organ system. Prognosis for untreated AL cardiac amyloidosis is poor, with a median survival of six months. More specifically, AL amyloidosis can be classified as stage I, II or III based on cardiac biomarkers like Nt-proBNP and cardiac troponin. Survival diminishes with increasing stage, however recent advancements in treatments have improved median survival rates for stages I, II, and III, to 91.2, 60, and 7 months respectively.
Outcomes in a person with AA amyloidosis depend on the underlying disease, organ(s) affected, and correlate with the concentration of serum amyloid A protein.
People with ATTR, mutant ATTR and wild-type ATTR have a better prognosis when compared to people with AL and may survive for over a decade. Survival time is not associated with gender or age, however, some measures of reduced heart function are associated with a shorter survival time.
AA amyloidoses is the most common form in developing countries and can complicate longstanding infections with tuberculosis, osteomyelitis, and bronchiectesis. AA amyloidosis is caused by an increase in extracellular deposition of serum amyloid A (SAA) protein. SAA protein levels can rise in both direct and indirect manners, through infection, inflammation, and malignancies. The most common causes of AA amyloidosis in the West are rheumatoid arthritis, inflammatory bowel disease, psoriasis, and familial Mediterranean fever.
People undergoing long-term hemodialysis (14–15 years) can develop amyloidosis from accumulation of light chains of the HLA 1 complex which is normally filtered out by the kidneys.
Wild-type transthyretin (ATTR) amyloidosis is found in a quarter of elderly at postmortem. ATTR is found in 13-19% of people experiencing heart failure with preserved ejection fraction, making it a very common form of systemic amyloidosis.
Treatments for ATTR-related neuropathy include TTR-specific oligonucleotides in the form of small interfering RNA (patisiran) or antisense inotersen, the former having recently received FDA approval. Research into treatments for ATTR amyloidosis have compared liver transplantation, oral drugs that stabilize the misfolding protein (including tafamidis and diflunisal), and newer therapeutic agents still being investigated (including patisiran). Based on available research, liver transplant remains the most effective treatment option for advanced ATTR amyloidosis, protein stabilizing drugs may slow disease progression but were insufficient to justify delay of liver transplant, and newer agents such as patisiran require additional studies.
- Hawkins P (29 April 2015). "AL amyloidosis". Wikilite.com. Archived from the original on 22 December 2015. Retrieved 19 December 2015.
- Hazenberg BP (May 2013). "Amyloidosis: a clinical overview". Rheumatic Disease Clinics of North America. 39 (2): 323–345. doi:10.1016/j.rdc.2013.02.012. PMID 23597967. S2CID 215069282.
- Pepys MB (2006). "Amyloidosis". Annual Review of Medicine. 57: 223–241. doi:10.1146/annurev.med.57.121304.131243. PMID 16409147.
- "AL amyloidosis". rarediseases.info.nih.gov. Genetic and Rare Diseases Information Center (GARD). Archived from the original on 24 April 2017. Retrieved 22 April 2017.
- Gertz MA, Dispenzieri A (July 2020). "Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review". JAMA. 324 (1): 79–89. doi:10.1001/jama.2020.5493. PMID 32633805. S2CID 220385853.
- Picken MM (2020). "The Pathology of Amyloidosis in Classification: A Review". Acta Haematologica. 143 (4): 322–334. doi:10.1159/000506696. PMID 32392555. S2CID 218600304.
- Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. (February 2013). "Guideline of transthyretin-related hereditary amyloidosis for clinicians". Orphanet Journal of Rare Diseases. 8: 31. doi:10.1186/1750-1172-8-31. PMC 3584981. PMID 23425518.
- "Amyloidosis & Kidney Disease". National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Department of Health and Human Services. Retrieved 19 November 2021.
- Lewis JB, Neilson EG (2018). "Glomerular Diseases". In Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (eds.). Harrison's Principles of Internal Medicine (20 ed.). McGraw Hill.
- Falk RH, Comenzo RL, Skinner M (September 1997). "The systemic amyloidoses". The New England Journal of Medicine. 337 (13): 898–909. doi:10.1056/NEJM199709253371306. PMID 9302305.
- Ebert EC, Nagar M (March 2008). "Gastrointestinal manifestations of amyloidosis". The American Journal of Gastroenterology. 103 (3): 776–787. PMID 18076735.
- Kyriakou P, Mouselimis D, Tsarouchas A, Rigopoulos A, Bakogiannis C, Noutsias M, Vassilikos V (December 2018). "Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers". BMC Cardiovascular Disorders. 18 (1): 221. doi:10.1186/s12872-018-0952-8. PMC 6278059. PMID 30509186.
- Kaku M, Berk JL (October 2019). "Neuropathy Associated with Systemic Amyloidosis". Seminars in Neurology. 39 (5): 578–588. doi:10.1055/s-0039-1688994. PMID 31639841. S2CID 204850185.
- Rowe K, Pankow J, Nehme F, Salyers W (May 2017). "Gastrointestinal Amyloidosis: Review of the Literature". Cureus. 9 (5): e1228. doi:10.7759/cureus.1228. PMC 5464793. PMID 28611935.
- Takahashi N, Glockner J, Howe BM, Hartman RP, Kawashima A (May 2016). "Taxonomy and Imaging Manifestations of Systemic Amyloidosis". Radiologic Clinics of North America. 54 (3): 597–612. doi:10.1016/j.rcl.2015.12.012. PMID 27153791.
- Eldhagen, P.; Berg, S.; Lund, L. H.; Sörensson, P.; Suhr, O. B.; Westermark, P. (June 2021). "Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis". Journal of Internal Medicine. 289 (6): 895–905. doi:10.1111/joim.13222. ISSN 1365-2796. PMC 8248398. PMID 33274477.
- Nguyen TX, Naqvi A, Thompson TL, Wilson RH (Spring 2018). "Musculoskeletal Manifestations of Amyloidosis: A Focused Review". Journal of Surgical Orthopaedic Advances. 27 (1): 1–5. PMID 29762107.
- Chiti F, Dobson CM (June 2017). "Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade". Annual Review of Biochemistry. 86: 27–68. doi:10.1146/annurev-biochem-061516-045115. PMID 28498720.
- Merlini G, Seldin DC, Gertz MA (May 2011). "Amyloidosis: pathogenesis and new therapeutic options". Journal of Clinical Oncology. 29 (14): 1924–1933. doi:10.1200/JCO.2010.32.2271. PMC 3138545. PMID 21483018.
- Gertz MA, Rajkumar SV (2010). Amyloidosis. Totowa, N.J.: Humana. ISBN 978-1-60761-631-3.
- Dember LM (December 2006). "Amyloidosis-associated kidney disease". Journal of the American Society of Nephrology. 17 (12): 3458–3471. doi:10.1681/ASN.2006050460. PMID 17093068. Archived from the original on 2011-12-05.
- Sachchithanantham S, Wechalekar AD (2013). "Imaging in systemic amyloidosis". British Medical Bulletin. 107: 41–56. doi:10.1093/bmb/ldt021. PMID 23896486.
- Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA (October 2018). "Systemic immunoglobulin light chain amyloidosis". Nature Reviews. Disease Primers. 4 (1): 38. doi:10.1038/s41572-018-0034-3. PMID 30361521. S2CID 53023121.
- Wechalekar AD, Gillmore JD, Hawkins PN (June 2016). "Systemic amyloidosis". Lancet. 387 (10038): 2641–2654. doi:10.1016/S0140-6736(15)01274-X. PMID 26719234. S2CID 4762107.
- Rosenzweig M, Landau H (November 2011). "Light chain (AL) amyloidosis: update on diagnosis and management". Journal of Hematology & Oncology. 4 (1): 47. doi:10.1186/1756-8722-4-47. PMC 3228694. PMID 22100031.
- Kazi, DS (2020). "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation". Circulation. 141 (15): 1214. doi:10.1161/CIRCULATIONAHA.119.045093.
- Mok KH, Pettersson J, Orrenius S, Svanborg C (March 2007). "HAMLET, protein folding, and tumor cell death". Biochemical and Biophysical Research Communications. 354 (1): 1–7. doi:10.1016/j.bbrc.2006.12.167. PMID 17223074.
- Pettersson-Kastberg J, Aits S, Gustafsson L, Mossberg A, Storm P, Trulsson M, et al. (November 2008). "Can misfolded proteins be beneficial? The HAMLET case". Annals of Medicine. 41 (3): 162–176. doi:10.1080/07853890802502614. PMID 18985467. S2CID 31198109.
- Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJ, Sekijima Y, et al. (December 2020). "Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee". Amyloid. 27 (4): 217–222. doi:10.1080/13506129.2020.1835263. PMID 33100054. S2CID 225073269.
- Table 5-12 in: Mitchell RS, Kumar V, Abbas AK, Fausto N (2007). Robbins Basic Pathology. Philadelphia: Saunders. ISBN 978-1-4160-2973-1. 8th edition.
- ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. (September 2015). "Recommendations for the management of autoinflammatory diseases". Annals of the Rheumatic Diseases. 74 (9): 1636–1644. doi:10.1136/annrheumdis-2015-207546. hdl:2445/108897. PMID 26109736. S2CID 18876892.
- Magrinelli F, Fabrizi GM, Santoro L, Manganelli F, Zanette G, Cavallaro T, Tamburin S, et al. (Cochrane Neuromuscular Group) (April 2020). "Pharmacological treatment for familial amyloid polyneuropathy". The Cochrane Database of Systematic Reviews. 4: CD012395. doi:10.1002/14651858.CD012395.pub2. PMC 7170468. PMID 32311072.
- Marques N, Azevedo O, Almeida AR, Bento D, Cruz I, Correia E, et al. (October 2020). "Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence-Based Recommendations". Journal of the American Heart Association. 9 (19): e016614. doi:10.1161/JAHA.120.016614. PMC 7792401. PMID 32969287.
- "Tegsedi". Europeans Medicines Agency.
- Mathew V, Wang AK (2019-05-06). "Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis". Drug Design, Development and Therapy. 13: 1515–1525. doi:10.2147/DDDT.S162913. PMC 6507904. PMID 31118583.
- "Patisiran for treating hereditary transthyretinrelated amyloidosis". Retrieved 20 July 2019.
- "Patisiran for treating hereditary transthyretin-related amyloidosis [ID1279] | Guidance | NICE". National Institute for Health and Care Excellence (Nice). Retrieved 20 July 2019.
- Hoy SM (October 2018). "Patisiran: First Global Approval". Drugs. 78 (15): 1625–1631. doi:10.1007/s40265-018-0983-6. PMID 30251172. S2CID 52813638.
- Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. (August 2021). "CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis". The New England Journal of Medicine. 385 (6): 493–502. doi:10.1056/NEJMoa2107454. PMID 34215024. S2CID 235722446.
- "Amyloidosis - NORD (National Organization for Rare Disorders)". NORD (National Organization for Rare Disorders). Archived from the original on 2016-03-16. Retrieved 2016-03-15.
- "Amyloidosis primary cutaneous – Disease – Organizations – Genetic and Rare Diseases Information Center (GARD) – NCATS Program". rarediseases.info.nih.gov. Archived from the original on 2016-03-15. Retrieved 2016-03-15.
- Merlini G (December 2017). "AL amyloidosis: from molecular mechanisms to targeted therapies". Hematology. American Society of Hematology. Education Program. 2017 (1): 1–12. doi:10.1182/asheducation-2017.1.1. PMC 6142527. PMID 29222231.
- Falk RH, Alexander KM, Liao R, Dorbala S (September 2016). "AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy". Journal of the American College of Cardiology. 68 (12): 1323–1341. doi:10.1016/j.jacc.2016.06.053. PMID 27634125.
- Xin Y, Hu W, Chen X, Hu J, Sun Y, Zhao Y (November 2019). "Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis: A systematic review and meta-analysis". Hellenic Journal of Cardiology. 60 (6): 375–383. doi:10.1016/j.hjc.2019.01.015. PMID 30742933. S2CID 73419672.
- Coles LS, Young RD (May 2012). "Supercentenarians and transthyretin amyloidosis: the next frontier of human life extension". Preventive Medicine. 54 (Suppl): S9-11. doi:10.1016/j.ypmed.2012.03.003. PMID 22579241.
- "Searching for the Secrets of the Super Old". Science. 26 September 2008. pp. 1764–1765. Archived from the original on 9 March 2013. Retrieved 22 February 2013.
- Lin HM, Gao X, Cooke CE, Berg D, Labotka R, Faller DV, et al. (June 2017). "Disease burden of systemic light-chain amyloidosis: a systematic literature review". Current Medical Research and Opinion. 33 (6): 1017–1031. doi:10.1080/03007995.2017.1297930. PMID 28277869. S2CID 205541963.
- Brunger AF, Nienhuis HL, Bijzet J, Hazenberg BP (March 2020). "Causes of AA amyloidosis: a systematic review". Amyloid. 27 (1): 1–12. doi:10.1080/13506129.2019.1693359. PMID 31766892. S2CID 208299494.
- Tanskanen, Maarit; Peuralinna, Terhi; Polvikoski, Tuomo; Notkola, Irma‐Leena; Sulkava, Raimo; Hardy, John; Singleton, Andrew; Kiuru‐Enari, Sari; Paetau, Anders; Tienari, Pentti J.; Myllykangas, Liisa (2008-01-01). "Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2‐macroglobulin and tau: A population‐based autopsy study". Annals of Medicine. 40 (3): 232–239. doi:10.1080/07853890701842988. ISSN 0785-3890. PMID 18382889.
- Hasib Sidiqi M, Gertz MA (May 2021). "Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021". Blood Cancer Journal. 11 (5): 90. doi:10.1038/s41408-021-00483-7. PMC 8124067. PMID 33993188.
- Buxbaum JN (July 2018). "Oligonucleotide Drugs for Transthyretin Amyloidosis". The New England Journal of Medicine. 379 (1): 82–85. doi:10.1056/nejme1805499. PMID 29972750. S2CID 49658028.
- Office of the Commissioner. "Press Announcements - FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease". www.fda.gov. Retrieved 2018-08-11.
- Cristóbal Gutiérrez H, Pelayo-Negro AL, Gómez Gómez D, Martín Vega MÁ, Valero Domínguez M (July 2020). "Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review". European Journal of Hospital Pharmacy. 27 (4): 194–201. doi:10.1136/ejhpharm-2018-001823. PMC 7335620. PMID 32587078.